High‐binding 96‐well ELISA plates (Costar) were coated overnight with 50 μL/well of vaccines and viral lysates diluted in PBS as follows: Vaxigrip (2014‐2015, Sanofi Pasteur), and GenHevac B (Sanofi Pasteur) at 1 μg/mL, and Revaxis (Sanofi Pasteur) and Priorix (GSK) at a 1:50 dilution. ELISA plates were also coated with protein lysates of adenovirus type 5, rhinovirus type 1A, and rotavirus (Zepto Metrix Corporation) at 5 μg/mL and purified trimeric YU‐2 gp140 protein at 2.5 μg/mL 22 . M. morganii (CIP 231T), E. faecalis (CIP 103241), E. cloacae (CIP 60.85T) were obtained from the biological resource center of Institut Pasteur (CRBIP), and E. coli used correspond to DH10β cells (NEB). Bacteria were grown as single colony, fixed with 0.2% paraformaldehyde (Sigma) for 20 min, washed, and used to coat Poly‐L‐Lysine‐treated High‐binding 96‐well ELISA plates (Costar) as previously described 16 . After washings with 0.05% Tween‐20‐PBS (PBST), plates were blocked 2 h with the ELISA blocking buffer. After washings with PBST, coated plates were incubated 2 h with recombinant IgG antibodies diluted to 1 μg/mL in PBS, and revealed as described above.
Priorix
Manufactured by GlaxoSmithKline
Sourced in United Kingdom, Germany
Priorix is a vaccine developed by GlaxoSmithKline. It is a live, attenuated vaccine that provides protection against measles, mumps, and rubella.
Automatically generated - may contain errors
Lab products found in correlation
Vaxigrip, by Sanofi (1 mentions)
High binding 96 well elisa plates, by Corning (1 mentions)
Genhevac b, by Sanofi (1 mentions)
Paraformaldehyde (pfa), by Merck Group (1 mentions)
Varilrix, by GlaxoSmithKline (1 mentions)
Priorix tetra, by GlaxoSmithKline (1 mentions)
Menitorix, by GlaxoSmithKline (1 mentions)
Infanrix hexa, by GlaxoSmithKline (1 mentions)
Rotateq, by Merck Group (1 mentions)
Pentaxim, by Sanofi (1 mentions)
Engerix b, by GlaxoSmithKline (1 mentions)
6 protocols using priorix
1
ELISA Screening of Antibody Binding
2
Comparative Evaluation of MMRV and Varicella Vaccines
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The administered MMRV was Priorix‐tetra (GSK), and the administered monovalent varicella vaccine was Varilrix (GSK), both containing the same live‐attenuated Oka VZV strain. The MMR used in the control group of this study was Priorix (GSK). Three lots of MMRV and monovalent varicella vaccine and one MMR lot were used. Vaccines were administered subcutaneously in the left deltoid region.
3
Comprehensive Arbovirus Detection Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Virus were obtained from several laboratories. SFV was from Pr Andres Merits in Estonia. ONNV, DENV species 1 to 4 and ZIKA virus were obtained from National Reference Laboratory for Arbovirus of Marseilles (France). RRV and SINV were purchased from the National Collection of Pathogenic Viruses (NCPV, UK). CHIKV strain clone #4.2 was isolated from a clinical sample in our laboratory during the CHIKV outbreak that occurred in Reunion Island in 2005 [32 (link)]. Other viruses used for validation studies were isolated from laboratory clinical samples. Rubella virus was detected using Priorix® (GlaxoSmithKline) a trivalent vaccine made of attenuated viral strains for measles virus, Myxovirus parotidis and Rubella.Additionally we used RNA standards for quantification of WEEV, EEEV, VEEV, BFV and CHIKV. RNA standards were purchased from Eurogentec and designed with RNA nucleotides using specific viral sequences selected at the location corresponding to the expected amplicon generated by our RT-PCR assay. Accession number of selected sequences was AM258995 (CHIKV), NC001786 (BFV), GQ287640 (WEEV), KC344475 (VEEV), KP282670 (EEEV).
4
Routine Infant Immunization Schedule
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
All infants received routine immunisations according to the Australian National Immunisation Program: at birth: intramuscular HepB vaccine (H-B-Vax II Paediatric® (bioCSL)); at 6 weeks, 4 and 6 months of age: intramuscular combined diphtheria-tetanus-acellular pertussis (DTPa)-HepB-inactivated polio (IPV)-Haemophilus influenzae type b (Hib) vaccine (Infanrix® hexa (GlaxoSmithKline)), intramuscular 13-valent conjugate pneumococcal vaccine (PCV13) (conjugated to CRM197, a diphtheria toxin) (Prevenar13® (Wyeth)), and oral rotavirus vaccine (RotaTeq® (Merck)); at 12 months of age: subcutaneous measles-mumps-rubella (MMR) vaccine (Priorix® (GlaxoSmithKline)) or (M-M-R®II (Seqirus)) and intramuscular combined Hib and meningococcal C vaccine (conjugated to tetanus toxin) (Menitorix® (GlaxoSmithKline)). Approximately half of the infants were randomised to receive intradermal BCG-Denmark (Statens Serum Institute, Copenhagen) shortly after birth as part of the MIS BAIR. None of the infants received an influenza vaccine. Vaccine records were obtained from the National Australian Immunisation register and/or individual immunisation records.
5
Pediatric Vaccine Immunization Schedule
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The immunization schedule for all vaccines followed routine practice for administration of the concomitant pediatric vaccines and is shown in PCV13+P80 or PCV13 w/o P80 (both 0.5 mL) was injected intramuscularly into the left anterolateral thigh muscle (lot numbers 7-5095-001A and 7-5093-003A, respectively). PCV13+P80 contains 2.2 μg of each saccharide, except for 4.4 μg of serotype 6B, per 0.5-mL dose. The final formulation contains 0.02% P80, 5 mM succinate buffer, with 0.125 mg of aluminum as aluminum phosphate per 0.5-mL dose. PCV13 w/o P80 was identical to PCV13+P80 with the exclusion of P80. Both PCV13+P80 and PCV13 w/o P80 were prefilled in identical syringes with a 1" needle length. Other routine vaccines administered were 0.5 mL combination diphtheria, tetanus and pertussis + inactivated poliovirus (types 1, 2 and 3) + Haemophilus influenzae type b vaccine (Pentaxim; Sanofi Pasteur, Swiftwater, PA; lot number infant vaccination Z2-155-2, lot number toddler vaccination A2061-1); 0.5 mL hepatitis B recombinant vaccine (Engerix-B; GlaxoSmithKline, London, United Kingdom; lot number AHBVB138AI); and 0.5 mL combined live measles, mumps, and rubella vaccine (Priorix; GlaxoSmithKline, London, United Kingdom; lot number A69CA683A). All were injected into right anterolateral thigh muscle.
6
Boosting Immunity with MMR Vaccine
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The recruitment of study subjects was conducted in accordance with the approval from the local ethical commission Charité-Universitätsmedizin Berlin (EA1/342/14) and informed consent in accordance with the Declaration of Helsinki. Fifteen healthy adults (5 male and 10 female; age±SEM = 34.67±2.11) with either documented measles, mumps, or rubella vaccination history or exposure through natural measles, mumps, or rubella infection were screened for their levels of pre-existing vaccine-reactive antibody titers (analyzed by Medizinisches Versorgungszentrum Labor Berlin). The donor's previous antigen exposure either by vaccination or by natural infection was verified by detectable antigen-reactive antibody titers. This study discusses results obtained from 11 donors who received a live attenuated measles-mumps-rubella (MMR) (Priorix®, GSK, Germany) booster vaccination.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!